Gossamer Bio (GOSS) & Its Rivals Critical Analysis

Gossamer Bio (NASDAQ:GOSS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Gossamer Bio to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings for Gossamer Bio and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	3	5	0	2.30
Gossamer Bio Competitors	9828	15119	45430	1586	2.54

Gossamer Bio currently has a consensus target price of $256.00, indicating a potential upside of 2,520.27%. As a group, “Biotechnology” companies have a potential upside of 101.04%. Given Gossamer Bio’s higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than its competitors.

Earnings and Valuation

This table compares Gossamer Bio and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Gossamer Bio	$53.29 million	-$170.37 million	-0.17
Gossamer Bio Competitors	$691.14 million	$10.43 million	-15.00

Gossamer Bio’s competitors have higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Gossamer Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Gossamer Bio Competitors	-9,046.59%	-199.78%	-30.61%

Volatility & Risk

Gossamer Bio has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Gossamer Bio’s competitors have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gossamer Bio competitors beat Gossamer Bio on 7 of the 13 factors compared.

Gossamer Bio Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.